{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:30:35Z","timestamp":1768721435128,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"Background<\/jats:title>Abdominal venous thromboses are rare thrombotic events with heterogeneous etiologies. They are related to myeloproliferative neoplasms (MPNs) in some patients and can occur as first signs of the disease. MPNs are characterized by mutations in the genes of Janus kinase 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL), and calreticulin (CALR).<\/jats:p><\/jats:sec>Methods<\/jats:title>Within the prospective trial \u201cPrevalence of JAK2 mutations in patients with abdominal venous thromboses\u201d (JAK2 MV study; German Clinical Trials Register: DRKS00026943), the peripheral blood of patients with abdominal venous thromboses in Mecklenburg-West Pomerania, a federal state located in north-east Germany, was analyzed by next-generation ultradeep sequencing for MPN-associated mutations. Clinical characteristics and blood cell counts were also of interest. The primary endpoint was the detection of the mutation JAK2<\/jats:italic> p.V617F. Secondary endpoints were the detection of other acquired variants of JAK2, as well as MPL and CALR.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 68 patients with abdominal venous thromboses were included from February 2017 to January 2021, with splanchnic veins affected in 65 patients. The mutation JAK2<\/jats:italic> p.V617F was present in 13 patients (19%), with four patients showing low variant allele frequencies (VAF 0.1% to 1.9%). The time interval from the thrombotic event to analysis was longer for patients with the mutation. The mutation MPL<\/jats:italic> p.W515R was detected in three cases, all of them with low VAF. One patient among them had a concurrent mutation of JAK2<\/jats:italic> p.V617F. The mutations CALR<\/jats:italic> type I or type II were not found.<\/jats:p><\/jats:sec>Discussion<\/jats:title>By analyzing peripheral blood for the mutation JAK2<\/jats:italic> p.V617F, an important cause of these rare thrombotic events can be identified. The development of a diagnostic workup with next-generation ultradeep sequencing for the analysis of the JAK2<\/jats:italic> p.V617F mutation and further mutations has the potential to better understand the etiology of abdominal venous thromboses in individual patients in regional clinical care, as abdominal venous thromboses are diagnosed by various medical disciplines.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1344769","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:32:45Z","timestamp":1704947565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Abdominal venous thromboses: detection of the JAK2 p.V617F mutation by next-generation ultradeep sequencing\u2014A prevalence study of patients in Mecklenburg-West Pomerania (2017\u20132021)"],"prefix":"10.3389","volume":"10","author":[{"given":"Larissa","family":"Henze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luise","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Felser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Grosse-Thie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrin","family":"Roolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther Adv Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/hematology.2021000237","article-title":"Clots in unusual places: lots of stress, limited data, critical decisions","volume":"2021","author":"Mathew","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00277-020-03965-z","article-title":"Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis","volume":"99","author":"Alvarez-Larr\u00e1n","year":"2020","journal-title":"Ann Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1478-3231.2008.01838.x","article-title":"Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience","volume":"29","author":"Rajani","year":"2009","journal-title":"Liver Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/bjs.6319","article-title":"Epidemiology, risk and prognostic factors in mesenteric venous thrombosis","volume":"95","author":"Acosta","year":"2008","journal-title":"Br J Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"Stefano V","year":"2016","journal-title":"Blood Cancer J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2021-153813","article-title":"Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban: a pilot, prospective cohort study","volume":"138","author":"Riva","year":"2021","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood.2020006827","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"137","author":"Valeriani","year":"2021","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1056786","DOI":"10.3389\/fonc.2022.1056786","article-title":"Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)","volume":"12","author":"Felser","year":"2022","journal-title":"Front Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00108-016-0120-0","article-title":"Frische ven\u00f6se Thrombose splanchnischer Gef\u00e4\u00dfe: Zwei Fallberichte zur kathetergest\u00fctzten lokalen Thrombolyse und -aspiration","volume":"58","author":"Praktiknjo","year":"2017","journal-title":"Internist."},{"key":"B12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/blood.2019000918","article-title":"Treatment of unusual thrombotic manifestations","volume":"135","author":"Abbattista","year":"2020","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","article-title":"Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation","volume":"132","author":"Colaizzo","year":"2013","journal-title":"Thromb Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1007\/s11033-023-08511-4","article-title":"Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms","volume":"50","author":"Demiriz","year":"2023","journal-title":"Mol Biol Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biom12020291","article-title":"JAK2 variant signaling: genetic, hematologic and immune implication in chronic myeloproliferative neoplasms","volume":"12","author":"Torres","year":"2022","journal-title":"Biomolecules."},{"key":"B19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/leu.2017.150","article-title":"Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era","volume":"31","author":"Falchi","year":"2017","journal-title":"Leukemia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","article-title":"The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis","volume":"5","author":"Colaizzo","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-020-00254-9","article-title":"Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania","volume":"8","author":"Grunwald","year":"2020","journal-title":"Biomark Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00277-018-3499-y","article-title":"Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls","volume":"98","author":"Maslah","year":"2019","journal-title":"Ann Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00277-023-05217-2","article-title":"Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort","volume":"102","author":"Cattaneo","year":"2023","journal-title":"Ann Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1160\/TH14-12-1055","article-title":"Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis","volume":"113","author":"Colaizzo","year":"2015","journal-title":"Thromb Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Advances."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and other acronyms: definition, implications, and impact on practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"Journal of Clin Inv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1182\/bloodadvances.2020003032","article-title":"Bleeding diathesis in mice lacking JAK2 in platelets","volume":"5","author":"Eaton","year":"2021","journal-title":"Blood Advances."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv."},{"key":"B33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br J Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11239-016-1337-4","article-title":"Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience","volume":"42","author":"Klute","year":"2016","journal-title":"J Thromb Thrombolysis."},{"key":"B35","unstructured":"2023"},{"key":"B36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/hematology.2021000270","article-title":"CHIP is clonal hematopoiesis a surrogate for aging and other disease?","volume":"2021","author":"Gondek","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/cells10123551","article-title":"Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives","volume":"10","author":"Baumeister","year":"2021","journal-title":"Cells."},{"key":"B38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/ijms24032262","article-title":"Shedding light on the pathogenesis of splanchnic vein thrombosis","volume":"24","author":"Camerlo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1344769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:32:49Z","timestamp":1704947569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1344769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":39,"alternative-id":["10.3389\/fmed.2023.1344769"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1344769","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"article-number":"1344769"}}